SG176265A1 - CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF - Google Patents

Info

Publication number

SG176265A1

SG176265A1 SG2011087723A SG2011087723A SG176265A1 SG 176265 A1 SG176265 A1 SG 176265A1 SG 2011087723 A SG2011087723 A SG 2011087723A SG 2011087723 A SG2011087723 A SG 2011087723A SG 176265 A1 SG176265 A1 SG 176265A1

Authority

SG

Singapore

Prior art keywords

antibody

binding

subject

fragment

binding fragment

Prior art date

2009-05-29

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 title claims abstract description 598
• 239000012634 fragment Substances 0.000 title claims abstract description 418
• 230000002526 effect on cardiovascular system Effects 0.000 title claims description 27
• 238000000034 method Methods 0.000 claims abstract description 425
• 230000007211 cardiovascular event Effects 0.000 claims abstract description 245
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 96
• 230000001154 acute effect Effects 0.000 claims abstract description 32
• 208000010125 myocardial infarction Diseases 0.000 claims description 127
• 102000000589 Interleukin-1 Human genes 0.000 claims description 118
• 108010002352 Interleukin-1 Proteins 0.000 claims description 118
• 230000000250 revascularization Effects 0.000 claims description 98
• 239000008194 pharmaceutical composition Substances 0.000 claims description 96
• 239000013543 active substance Substances 0.000 claims description 76
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 63
• 208000006011 Stroke Diseases 0.000 claims description 61
• 206010019280 Heart failures Diseases 0.000 claims description 59
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 54
• 206010002383 Angina Pectoris Diseases 0.000 claims description 53
• 206010020772 Hypertension Diseases 0.000 claims description 49
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 40
• 108010074051 C-Reactive Protein Proteins 0.000 claims description 39
• 102100032752 C-reactive protein Human genes 0.000 claims description 39
• 210000004369 blood Anatomy 0.000 claims description 39
• 239000008280 blood Substances 0.000 claims description 39
• 230000034994 death Effects 0.000 claims description 37
• 231100000517 death Toxicity 0.000 claims description 37
• 208000020832 chronic kidney disease Diseases 0.000 claims description 29
• 238000001356 surgical procedure Methods 0.000 claims description 29
• 201000001320 Atherosclerosis Diseases 0.000 claims description 26
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 24
• 230000002093 peripheral effect Effects 0.000 claims description 24
• 150000001413 amino acids Chemical class 0.000 claims description 23
• 238000010494 dissociation reaction Methods 0.000 claims description 23
• 230000005593 dissociations Effects 0.000 claims description 23
• 208000010496 Heart Arrest Diseases 0.000 claims description 22
• 208000029078 coronary artery disease Diseases 0.000 claims description 20
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
• 238000013146 percutaneous coronary intervention Methods 0.000 claims description 19
• 230000036772 blood pressure Effects 0.000 claims description 18
• 235000012000 cholesterol Nutrition 0.000 claims description 18
• 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 17
• 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 17
• 229940030600 antihypertensive agent Drugs 0.000 claims description 17
• 239000002220 antihypertensive agent Substances 0.000 claims description 17
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 17
• 206010061218 Inflammation Diseases 0.000 claims description 16
• 210000004351 coronary vessel Anatomy 0.000 claims description 16
• 230000004054 inflammatory process Effects 0.000 claims description 16
• 208000037803 restenosis Diseases 0.000 claims description 16
• 239000008103 glucose Substances 0.000 claims description 15
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 14
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 14
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 14
• 239000003112 inhibitor Substances 0.000 claims description 14
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 13
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 13
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 13
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 13
• 208000008589 Obesity Diseases 0.000 claims description 13
• 208000007536 Thrombosis Diseases 0.000 claims description 13
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 13
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 13
• 229960003711 glyceryl trinitrate Drugs 0.000 claims description 13
• 201000001421 hyperglycemia Diseases 0.000 claims description 13
• 235000020824 obesity Nutrition 0.000 claims description 13
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 12
• 239000003146 anticoagulant agent Substances 0.000 claims description 12
• 230000000391 smoking effect Effects 0.000 claims description 11
• 230000009885 systemic effect Effects 0.000 claims description 11
• 206010027525 Microalbuminuria Diseases 0.000 claims description 10
• 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 10
• 239000007943 implant Substances 0.000 claims description 10
• 206010014486 Elevated triglycerides Diseases 0.000 claims description 9
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 9
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 9
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 9
• 239000000006 Nitroglycerin Substances 0.000 claims description 9
• 102000003982 Parathyroid hormone Human genes 0.000 claims description 9
• 108090000445 Parathyroid hormone Proteins 0.000 claims description 9
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 9
• 208000032109 Transient ischaemic attack Diseases 0.000 claims description 9
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 9
• 239000002876 beta blocker Substances 0.000 claims description 9
• 238000013172 carotid endarterectomy Methods 0.000 claims description 9
• 239000002934 diuretic Substances 0.000 claims description 9
• 229960002237 metoprolol Drugs 0.000 claims description 9
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 9
• 229960001783 nicardipine Drugs 0.000 claims description 9
• 239000000199 parathyroid hormone Substances 0.000 claims description 9
• 229960001319 parathyroid hormone Drugs 0.000 claims description 9
• 238000007888 peripheral angioplasty Methods 0.000 claims description 9
• 239000011574 phosphorus Substances 0.000 claims description 9
• 229910052698 phosphorus Inorganic materials 0.000 claims description 9
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 8
• 229960001138 acetylsalicylic acid Drugs 0.000 claims description 8
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 8
• 239000000480 calcium channel blocker Substances 0.000 claims description 8
• 229940124549 vasodilator Drugs 0.000 claims description 8
• 239000003071 vasodilator agent Substances 0.000 claims description 8
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical group C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 7
• 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 7
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 7
• 229960003597 clevidipine Drugs 0.000 claims description 7
• KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 claims description 7
• XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 7
• 229960002474 hydralazine Drugs 0.000 claims description 7
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 7
• 229960001632 labetalol Drugs 0.000 claims description 7
• 229940083618 sodium nitroprusside Drugs 0.000 claims description 7
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 6
• 238000008214 LDL Cholesterol Methods 0.000 claims description 6
• 230000003276 anti-hypertensive effect Effects 0.000 claims description 6
• 239000003529 anticholesteremic agent Substances 0.000 claims description 6
• 229940127226 anticholesterol agent Drugs 0.000 claims description 6
• 229940127219 anticoagulant drug Drugs 0.000 claims description 6
• 206010012601 diabetes mellitus Diseases 0.000 claims description 6
• 230000001882 diuretic effect Effects 0.000 claims description 6
• 230000001631 hypertensive effect Effects 0.000 claims description 6
• 239000003087 receptor blocking agent Substances 0.000 claims description 6
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 6
• 230000002537 thrombolytic effect Effects 0.000 claims description 6
• 229940097420 Diuretic Drugs 0.000 claims description 5
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
• 229940097320 beta blocking agent Drugs 0.000 claims description 5
• 229960003512 nicotinic acid Drugs 0.000 claims description 5
• 235000001968 nicotinic acid Nutrition 0.000 claims description 5
• 239000011664 nicotinic acid Substances 0.000 claims description 5
• 102000008873 Angiotensin II receptor Human genes 0.000 claims description 4
• 108050000824 Angiotensin II receptor Proteins 0.000 claims description 4
• 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 4
• 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 4
• 229940071643 prefilled syringe Drugs 0.000 claims description 4
• 238000010255 intramuscular injection Methods 0.000 claims description 3
• 239000007927 intramuscular injection Substances 0.000 claims description 3
• 238000010253 intravenous injection Methods 0.000 claims description 3
• 230000003472 neutralizing effect Effects 0.000 claims description 3
• 238000010254 subcutaneous injection Methods 0.000 claims description 3
• 241000208125 Nicotiana Species 0.000 claims 3
• 241000208011 Digitalis Species 0.000 claims 2
• 238000011282 treatment Methods 0.000 abstract description 58
• 230000009467 reduction Effects 0.000 abstract description 36
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
• 201000010099 disease Diseases 0.000 abstract description 27
• 230000002265 prevention Effects 0.000 abstract description 23
• 230000001684 chronic effect Effects 0.000 abstract description 21
• -1 abciximab Chemical compound 0.000 description 66
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 58
• 102100039065 Interleukin-1 beta Human genes 0.000 description 58
• 239000000427 antigen Substances 0.000 description 51
• 102000036639 antigens Human genes 0.000 description 51
• 108091007433 antigens Proteins 0.000 description 51
• 108090000765 processed proteins & peptides Proteins 0.000 description 50
• 108090000623 proteins and genes Proteins 0.000 description 49
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 46
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 46
• 239000000203 mixture Substances 0.000 description 43
• 102000004196 processed proteins & peptides Human genes 0.000 description 37
• 206010000891 acute myocardial infarction Diseases 0.000 description 33
• 102000004169 proteins and genes Human genes 0.000 description 33
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 30
• 241001465754 Metazoa Species 0.000 description 30
• 241000699670 Mus sp. Species 0.000 description 29
• 235000001014 amino acid Nutrition 0.000 description 27
• 230000000694 effects Effects 0.000 description 26
• 238000004519 manufacturing process Methods 0.000 description 26
• 229920001184 polypeptide Polymers 0.000 description 26
• 235000018102 proteins Nutrition 0.000 description 26
• 229940024606 amino acid Drugs 0.000 description 24
• 238000003556 assay Methods 0.000 description 21
• 229920000642 polymer Polymers 0.000 description 21
• 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 20
• 238000002823 phage display Methods 0.000 description 20
• 108090001007 Interleukin-8 Proteins 0.000 description 18
• 102000004890 Interleukin-8 Human genes 0.000 description 18
• 230000006870 function Effects 0.000 description 18
• 230000005764 inhibitory process Effects 0.000 description 18
• 210000002966 serum Anatomy 0.000 description 18
• 108060003951 Immunoglobulin Proteins 0.000 description 17
• 241000699666 Mus <mouse, genus> Species 0.000 description 17
• 230000035487 diastolic blood pressure Effects 0.000 description 17
• 102000018358 immunoglobulin Human genes 0.000 description 17
• 238000006467 substitution reaction Methods 0.000 description 17
• 230000035488 systolic blood pressure Effects 0.000 description 17
• 210000004027 cell Anatomy 0.000 description 16
• 229940107161 cholesterol Drugs 0.000 description 16
• 238000004458 analytical method Methods 0.000 description 15
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
• 230000000747 cardiac effect Effects 0.000 description 15
• 238000009472 formulation Methods 0.000 description 15
• 238000005259 measurement Methods 0.000 description 15
• 125000003275 alpha amino acid group Chemical group 0.000 description 14
• 102000004127 Cytokines Human genes 0.000 description 13
• 108090000695 Cytokines Proteins 0.000 description 13
• 150000001875 compounds Chemical class 0.000 description 13
• 239000003814 drug Substances 0.000 description 13
• 230000014509 gene expression Effects 0.000 description 13
• 229940068196 placebo Drugs 0.000 description 13
• 239000000902 placebo Substances 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 12
• 239000003550 marker Substances 0.000 description 12
• 238000012216 screening Methods 0.000 description 12
• 108010023302 HDL Cholesterol Proteins 0.000 description 11
• 108090001005 Interleukin-6 Proteins 0.000 description 11
• 102000004889 Interleukin-6 Human genes 0.000 description 11
• 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 238000011084 recovery Methods 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 206010061216 Infarction Diseases 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 210000002216 heart Anatomy 0.000 description 10
• 150000002632 lipids Chemical class 0.000 description 10
• 150000007523 nucleic acids Chemical class 0.000 description 10
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 125000000539 amino acid group Chemical group 0.000 description 9
• 230000007574 infarction Effects 0.000 description 9
• 238000001990 intravenous administration Methods 0.000 description 9
• 230000003902 lesion Effects 0.000 description 9
• 125000005647 linker group Chemical group 0.000 description 9
• 238000011477 surgical intervention Methods 0.000 description 9
• 102000015779 HDL Lipoproteins Human genes 0.000 description 8
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
• 108020004707 nucleic acids Proteins 0.000 description 8
• 102000039446 nucleic acids Human genes 0.000 description 8
• 238000002203 pretreatment Methods 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 239000013598 vector Substances 0.000 description 8
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 7
• 102000008186 Collagen Human genes 0.000 description 7
• 108010035532 Collagen Proteins 0.000 description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
• 244000061176 Nicotiana tabacum Species 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 210000000709 aorta Anatomy 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 239000011230 binding agent Substances 0.000 description 7
• 229920001436 collagen Polymers 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 229920002674 hyaluronan Polymers 0.000 description 7
• 230000003053 immunization Effects 0.000 description 7
• 230000005847 immunogenicity Effects 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 208000028867 ischemia Diseases 0.000 description 7
• 210000002540 macrophage Anatomy 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 230000036470 plasma concentration Effects 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 229940044551 receptor antagonist Drugs 0.000 description 7
• 239000002464 receptor antagonist Substances 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 230000009261 transgenic effect Effects 0.000 description 7
• 230000002861 ventricular Effects 0.000 description 7
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 108020004511 Recombinant DNA Proteins 0.000 description 6
• ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 229960003160 hyaluronic acid Drugs 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 238000013268 sustained release Methods 0.000 description 6
• 239000012730 sustained-release form Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 5
• 241000282832 Camelidae Species 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 5
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 5
• 102000003810 Interleukin-18 Human genes 0.000 description 5
• 108090000171 Interleukin-18 Proteins 0.000 description 5
• 108010028554 LDL Cholesterol Proteins 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 210000001367 artery Anatomy 0.000 description 5
• 230000003143 atherosclerotic effect Effects 0.000 description 5
• 229920002678 cellulose Polymers 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 230000003205 diastolic effect Effects 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 238000011156 evaluation Methods 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 230000000302 ischemic effect Effects 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
• 239000004094 surface-active agent Substances 0.000 description 5
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
• JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 4
• 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 4
• 206010002388 Angina unstable Diseases 0.000 description 4
• 235000002198 Annona diversifolia Nutrition 0.000 description 4
• 239000002083 C09CA01 - Losartan Substances 0.000 description 4
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 4
• 238000011740 C57BL/6 mouse Methods 0.000 description 4
• 240000001879 Digitalis lutea Species 0.000 description 4
• 108010056764 Eptifibatide Proteins 0.000 description 4
• 102000009109 Fc receptors Human genes 0.000 description 4
• 108010087819 Fc receptors Proteins 0.000 description 4
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
• 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 4
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 4
• 108010007859 Lisinopril Proteins 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 208000007814 Unstable Angina Diseases 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 229960000528 amlodipine Drugs 0.000 description 4
• 230000005875 antibody response Effects 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 230000017531 blood circulation Effects 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 229960000830 captopril Drugs 0.000 description 4
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 210000001715 carotid artery Anatomy 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 229960001523 chlortalidone Drugs 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 238000013270 controlled release Methods 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 230000016396 cytokine production Effects 0.000 description 4
• 230000002354 daily effect Effects 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 238000006731 degradation reaction Methods 0.000 description 4
• 238000002405 diagnostic procedure Methods 0.000 description 4
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
• 229960004166 diltiazem Drugs 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 229960004468 eptifibatide Drugs 0.000 description 4
• GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 229960003883 furosemide Drugs 0.000 description 4
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
• 210000004408 hybridoma Anatomy 0.000 description 4
• 229960002003 hydrochlorothiazide Drugs 0.000 description 4
• 239000000017 hydrogel Substances 0.000 description 4
• NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 4
• 229960004569 indapamide Drugs 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 238000009533 lab test Methods 0.000 description 4
• 229960002394 lisinopril Drugs 0.000 description 4
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 4
• 229960004773 losartan Drugs 0.000 description 4
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 4
• 229960002817 metolazone Drugs 0.000 description 4
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 4
• 229960004255 nadolol Drugs 0.000 description 4
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
• 229960001597 nifedipine Drugs 0.000 description 4
• KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 4
• 229960002035 penbutolol Drugs 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000000770 proinflammatory effect Effects 0.000 description 4
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 4
• 229960003401 ramipril Drugs 0.000 description 4
• 238000002702 ribosome display Methods 0.000 description 4
• 230000000276 sedentary effect Effects 0.000 description 4
• 230000005586 smoking cessation Effects 0.000 description 4
• 229940083542 sodium Drugs 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 4
• 229960002256 spironolactone Drugs 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 238000010967 transthoracic echocardiography Methods 0.000 description 4
• 238000011269 treatment regimen Methods 0.000 description 4
• 229960004699 valsartan Drugs 0.000 description 4
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• 229960001722 verapamil Drugs 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• 108010088751 Albumins Proteins 0.000 description 3
• 102000009027 Albumins Human genes 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 102000013918 Apolipoproteins E Human genes 0.000 description 3
• 108010025628 Apolipoproteins E Proteins 0.000 description 3
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
• 241000282836 Camelus dromedarius Species 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 241000724791 Filamentous phage Species 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• 102000007330 LDL Lipoproteins Human genes 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 229920000954 Polyglycolide Polymers 0.000 description 3
• 241000191963 Staphylococcus epidermidis Species 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 229960004238 anakinra Drugs 0.000 description 3
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 239000000227 bioadhesive Substances 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000004067 bulking agent Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• 239000002131 composite material Substances 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 229940030606 diuretics Drugs 0.000 description 3
• 238000002592 echocardiography Methods 0.000 description 3
• 208000028208 end stage renal disease Diseases 0.000 description 3
• 201000000523 end stage renal failure Diseases 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 238000012417 linear regression Methods 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
• 239000003471 mutagenic agent Substances 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000001766 physiological effect Effects 0.000 description 3
• 229920001983 poloxamer Polymers 0.000 description 3
• 229920000747 poly(lactic acid) Polymers 0.000 description 3
• 229920000573 polyethylene Polymers 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• 229920002451 polyvinyl alcohol Polymers 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 3
• 229960001455 quinapril Drugs 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
• HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 2
• YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
• FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
• DIHXSRXTECMMJY-MURFETPASA-N 2-[dimethyl-[(9z,12z)-octadeca-9,12-dienyl]azaniumyl]acetate Chemical group CCCCC\C=C/C\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O DIHXSRXTECMMJY-MURFETPASA-N 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
• 108010064733 Angiotensins Proteins 0.000 description 2
• 102000015427 Angiotensins Human genes 0.000 description 2
• 244000303258 Annona diversifolia Species 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
• 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
• 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 206010008479 Chest Pain Diseases 0.000 description 2
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 229920001353 Dextrin Polymers 0.000 description 2
• 239000004375 Dextrin Substances 0.000 description 2
• 206010052337 Diastolic dysfunction Diseases 0.000 description 2
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
• 102000017914 EDNRA Human genes 0.000 description 2
• 108010061435 Enalapril Proteins 0.000 description 2
• 108010090549 Endothelin A Receptor Proteins 0.000 description 2
• 239000001856 Ethyl cellulose Substances 0.000 description 2
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 2
• INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 108010007267 Hirudins Proteins 0.000 description 2
• 102000007625 Hirudins Human genes 0.000 description 2
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• 102000039996 IL-1 family Human genes 0.000 description 2
• 108091069196 IL-1 family Proteins 0.000 description 2
• 241000282838 Lama Species 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
• UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 235000009421 Myristica fragrans Nutrition 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 208000034827 Neointima Diseases 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 239000005480 Olmesartan Substances 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 2
• CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 229920002125 Sokalan® Polymers 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 108010023197 Streptokinase Proteins 0.000 description 2
• 102100030416 Stromelysin-1 Human genes 0.000 description 2
• 101710108790 Stromelysin-1 Proteins 0.000 description 2
• 206010071436 Systolic dysfunction Diseases 0.000 description 2
• 108700012920 TNF Proteins 0.000 description 2
• 108010039185 Tenecteplase Proteins 0.000 description 2
• 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
• 229940121792 Thiazide diuretic Drugs 0.000 description 2
• 229940122388 Thrombin inhibitor Drugs 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 2
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
• 102000013394 Troponin I Human genes 0.000 description 2
• 108010065729 Troponin I Proteins 0.000 description 2
• 102000004987 Troponin T Human genes 0.000 description 2
• 108090001108 Troponin T Proteins 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 108010069201 VLDL Cholesterol Proteins 0.000 description 2
• 229920002494 Zein Polymers 0.000 description 2
• 229960000446 abciximab Drugs 0.000 description 2
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
• 229960002122 acebutolol Drugs 0.000 description 2
• 229960002054 acenocoumarol Drugs 0.000 description 2
• VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 239000000674 adrenergic antagonist Substances 0.000 description 2
• 230000009824 affinity maturation Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 229960002478 aldosterone Drugs 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 239000002160 alpha blocker Substances 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• 229960003318 alteplase Drugs 0.000 description 2
• 229960002576 amiloride Drugs 0.000 description 2
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
• 229960004104 amiloride hydrochloride Drugs 0.000 description 2
• LTKVFMLMEYCWMK-UHFFFAOYSA-N amiloride hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N LTKVFMLMEYCWMK-UHFFFAOYSA-N 0.000 description 2
• 229960004005 amlodipine besylate Drugs 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 210000000628 antibody-producing cell Anatomy 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 206010003119 arrhythmia Diseases 0.000 description 2
• 230000006793 arrhythmia Effects 0.000 description 2
• 229960002274 atenolol Drugs 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 229960005370 atorvastatin Drugs 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 229960004530 benazepril Drugs 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 2
• 229960001541 benzthiazide Drugs 0.000 description 2
• 229960004324 betaxolol Drugs 0.000 description 2
• NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 229920001222 biopolymer Polymers 0.000 description 2
• 229960002781 bisoprolol Drugs 0.000 description 2
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
• 108010055460 bivalirudin Proteins 0.000 description 2
• OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
• 229960001500 bivalirudin Drugs 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 229960000932 candesartan Drugs 0.000 description 2
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 210000004413 cardiac myocyte Anatomy 0.000 description 2
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
• 229960001222 carteolol Drugs 0.000 description 2
• 229960004195 carvedilol Drugs 0.000 description 2
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical group COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
• 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
• 229960005110 cerivastatin Drugs 0.000 description 2
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 229960002155 chlorothiazide Drugs 0.000 description 2
• 229960004588 cilostazol Drugs 0.000 description 2
• RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
• 229960002896 clonidine Drugs 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 229960003009 clopidogrel Drugs 0.000 description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
• 238000003501 co-culture Methods 0.000 description 2
• 239000008139 complexing agent Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 239000006184 cosolvent Substances 0.000 description 2
• 238000009223 counseling Methods 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 239000007857 degradation product Substances 0.000 description 2
• 230000003413 degradative effect Effects 0.000 description 2
• 235000019425 dextrin Nutrition 0.000 description 2
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
• 229960005156 digoxin Drugs 0.000 description 2
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
• 229960002768 dipyridamole Drugs 0.000 description 2
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
• 229960001389 doxazosin Drugs 0.000 description 2
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
• 238000001378 electrochemiluminescence detection Methods 0.000 description 2
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
• 229960000873 enalapril Drugs 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 229960004563 eprosartan Drugs 0.000 description 2
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
• 230000003628 erosive effect Effects 0.000 description 2
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
• 229960003745 esmolol Drugs 0.000 description 2
• 235000019325 ethyl cellulose Nutrition 0.000 description 2
• 229920001249 ethyl cellulose Polymers 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
• 229960000815 ezetimibe Drugs 0.000 description 2
• 229960003580 felodipine Drugs 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 229960003765 fluvastatin Drugs 0.000 description 2
• 210000000497 foam cell Anatomy 0.000 description 2
• 229960002490 fosinopril Drugs 0.000 description 2
• 235000021588 free fatty acids Nutrition 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 229960004553 guanabenz Drugs 0.000 description 2
• HPBNRIOWIXYZFK-UHFFFAOYSA-N guanadrel Chemical compound O1C(CNC(=N)N)COC11CCCCC1 HPBNRIOWIXYZFK-UHFFFAOYSA-N 0.000 description 2
• 229960003845 guanadrel Drugs 0.000 description 2
• ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 2
• 229960003602 guanethidine Drugs 0.000 description 2
• 229960002048 guanfacine Drugs 0.000 description 2
• 230000004217 heart function Effects 0.000 description 2
• 210000003709 heart valve Anatomy 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 229940006607 hirudin Drugs 0.000 description 2
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000008105 immune reaction Effects 0.000 description 2
• 230000002998 immunogenetic effect Effects 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 229960002198 irbesartan Drugs 0.000 description 2
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
• 229960000201 isosorbide dinitrate Drugs 0.000 description 2
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
• 229960003827 isosorbide mononitrate Drugs 0.000 description 2
• 229960004427 isradipine Drugs 0.000 description 2
• 238000012933 kinetic analysis Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 201000002818 limb ischemia Diseases 0.000 description 2
• 229960004844 lovastatin Drugs 0.000 description 2
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
• 239000003055 low molecular weight heparin Substances 0.000 description 2
• 229940127215 low-molecular weight heparin Drugs 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 239000012931 lyophilized formulation Substances 0.000 description 2
• 239000001115 mace Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229960002525 mecamylamine Drugs 0.000 description 2
• IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 2
• VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 229950009116 mevastatin Drugs 0.000 description 2
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 229960003632 minoxidil Drugs 0.000 description 2
• 229960005170 moexipril Drugs 0.000 description 2
• 229960004715 morphine sulfate Drugs 0.000 description 2
• GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 238000013164 myectomy Methods 0.000 description 2
• 229920005615 natural polymer Polymers 0.000 description 2
• 229960001267 nesiritide Drugs 0.000 description 2
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 229960000227 nisoldipine Drugs 0.000 description 2
• JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 229960005117 olmesartan Drugs 0.000 description 2
• VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
• 229960002582 perindopril Drugs 0.000 description 2
• 208000030613 peripheral artery disease Diseases 0.000 description 2
• 229960004923 phenprocoumon Drugs 0.000 description 2
• DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 229960002508 pindolol Drugs 0.000 description 2
• JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 2
• 229960002797 pitavastatin Drugs 0.000 description 2
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
• 229920001281 polyalkylene Polymers 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 150000004804 polysaccharides Chemical class 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 229940068965 polysorbates Drugs 0.000 description 2
• 229960005483 polythiazide Drugs 0.000 description 2
• 229920000046 polythiazide Polymers 0.000 description 2
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
• 229960002965 pravastatin Drugs 0.000 description 2
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
• 229960001289 prazosin Drugs 0.000 description 2
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 235000013930 proline Nutrition 0.000 description 2
• 229960003712 propranolol Drugs 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 229960002231 ramiprilat Drugs 0.000 description 2
• KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 239000002461 renin inhibitor Substances 0.000 description 2
• 229940086526 renin-inhibitors Drugs 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229960003147 reserpine Drugs 0.000 description 2
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
• 108010051412 reteplase Proteins 0.000 description 2
• 229960002917 reteplase Drugs 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
• 229960000672 rosuvastatin Drugs 0.000 description 2
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000004904 shortening Methods 0.000 description 2
• 229960002855 simvastatin Drugs 0.000 description 2
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 238000012289 standard assay Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229960005202 streptokinase Drugs 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 229920001059 synthetic polymer Polymers 0.000 description 2
• 229960005187 telmisartan Drugs 0.000 description 2
• 229960000216 tenecteplase Drugs 0.000 description 2
• VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
• 229960001693 terazosin Drugs 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 239000003451 thiazide diuretic agent Substances 0.000 description 2
• 239000003868 thrombin inhibitor Substances 0.000 description 2
• 229960005001 ticlopidine Drugs 0.000 description 2
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
• 229960004605 timolol Drugs 0.000 description 2
• 229960003425 tirofiban Drugs 0.000 description 2
• COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
• 229960005461 torasemide Drugs 0.000 description 2
• 229960002051 trandolapril Drugs 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• 229960001288 triamterene Drugs 0.000 description 2
• LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 2
• 229960004813 trichlormethiazide Drugs 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 238000002604 ultrasonography Methods 0.000 description 2
• 229960005356 urokinase Drugs 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 229960005080 warfarin Drugs 0.000 description 2
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
• 229920003169 water-soluble polymer Polymers 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 239000005019 zein Substances 0.000 description 2
• 229940093612 zein Drugs 0.000 description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
• RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
• LMVGXBRDRZOPHA-UHFFFAOYSA-N 2-[dimethyl-[3-(16-methylheptadecanoylamino)propyl]azaniumyl]acetate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O LMVGXBRDRZOPHA-UHFFFAOYSA-N 0.000 description 1
• TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
• SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
• DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 description 1
• VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
• 102220566030 5-hydroxytryptamine receptor 2B_N55S_mutation Human genes 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 101710186708 Agglutinin Proteins 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 101710095342 Apolipoprotein B Proteins 0.000 description 1
• 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 229930091051 Arenine Natural products 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000031648 Body Weight Changes Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 108010075254 C-Peptide Proteins 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 108090000613 Cathepsin S Proteins 0.000 description 1
• 102100035654 Cathepsin S Human genes 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
• 229920002284 Cellulose triacetate Polymers 0.000 description 1
• 206010051290 Central nervous system lesion Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014476 Elevated cholesterol Diseases 0.000 description 1
• 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
• 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• 108010058643 Fungal Proteins Proteins 0.000 description 1
• 241000251152 Ginglymostoma cirratum Species 0.000 description 1
• 241001416183 Ginglymostomatidae Species 0.000 description 1
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
• 101710146024 Horcolin Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 241000251471 Hydrolagus colliei Species 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 102000016551 L-selectin Human genes 0.000 description 1
• 244000147568 Laurus nobilis Species 0.000 description 1
• 235000017858 Laurus nobilis Nutrition 0.000 description 1
• 101710189395 Lectin Proteins 0.000 description 1
• 108091036060 Linker DNA Proteins 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 229920002774 Maltodextrin Polymers 0.000 description 1
• 239000005913 Maltodextrin Substances 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 101710179758 Mannose-specific lectin Proteins 0.000 description 1
• 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
• 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
• 241000415294 Orectolobidae Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102000004211 Platelet factor 4 Human genes 0.000 description 1
• 108090000778 Platelet factor 4 Proteins 0.000 description 1
• 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
• 108010055044 Tetanus Toxin Proteins 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 102100030859 Tissue factor Human genes 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102000004903 Troponin Human genes 0.000 description 1
• 108090001027 Troponin Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000000910 agglutinin Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910001508 alkali metal halide Inorganic materials 0.000 description 1
• 150000008045 alkali metal halides Chemical class 0.000 description 1
• 229920013820 alkyl cellulose Polymers 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 210000000702 aorta abdominal Anatomy 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000000923 atherogenic effect Effects 0.000 description 1
• 230000007214 atherothrombosis Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 230000004579 body weight change Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 229960001838 canakinumab Drugs 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 230000003293 cardioprotective effect Effects 0.000 description 1
• 210000001168 carotid artery common Anatomy 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 229920003086 cellulose ether Polymers 0.000 description 1
• 229920006218 cellulose propionate Polymers 0.000 description 1
• 230000003727 cerebral blood flow Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• 150000001840 cholesterol esters Chemical class 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000010372 cloning stem cell Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 229940096516 dextrates Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229960003699 evans blue Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000001308 heart ventricle Anatomy 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 235000009200 high fat diet Nutrition 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 102000043959 human IL18 Human genes 0.000 description 1
• 102000054751 human RUNX1T1 Human genes 0.000 description 1
• 229940099552 hyaluronan Drugs 0.000 description 1
• KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000003601 intercostal effect Effects 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 239000002563 ionic surfactant Substances 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 229940054136 kineret Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000002824 mRNA display Methods 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 229940035034 maltodextrin Drugs 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 125000005395 methacrylic acid group Chemical group 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 210000003657 middle cerebral artery Anatomy 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 239000002062 molecular scaffold Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 238000007491 morphometric analysis Methods 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• NZXVYLJKFYSEPO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCCN(C)C NZXVYLJKFYSEPO-UHFFFAOYSA-N 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000003516 pericardium Anatomy 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 108700010839 phage proteins Proteins 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229940044519 poloxamer 188 Drugs 0.000 description 1
• 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
• 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
• 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
• 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
• 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 229920000139 polyethylene terephthalate Polymers 0.000 description 1
• 239000005020 polyethylene terephthalate Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229920000129 polyhexylmethacrylate Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 229920000182 polyphenyl methacrylate Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920001290 polyvinyl ester Polymers 0.000 description 1
• 229920001289 polyvinyl ether Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 210000003291 sinus of valsalva Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 208000023516 stroke disease Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940104261 taurate Drugs 0.000 description 1
• 229940118376 tetanus toxin Drugs 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 210000003813 thumb Anatomy 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 239000012443 tonicity enhancing agent Substances 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000000207 volumetry Methods 0.000 description 1